SCHEMBL41322

SCHEMBL41322

O=[N+]([O-])c1ccc[c]c1O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR35 Q9HC97 2/20 0.54
TDP1 Q9NUW8 5/20 0.45
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 2/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
ERN1 O75460 1/20 0.43
HSD17B10 Q99714 1/20 0.42
CTSB P07858 1/20 0.41
ALDH1A1 P00352 4/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
CASP7 P55210 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
TSHR P16473 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PLAU P00749 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7086751 0.79 PTPN11 (0.50) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL7136437 0.77 TDP1 (0.46) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL33832 0.77 TDP1 (0.46) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL1036583 0.75 TDP1 (0.45) GPR35TDP1KMT2AMEN1GAA
SCHEMBL1179475 0.75 TDP1 (0.45) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL7907932 0.75 TDP1 (0.45) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL2075134 0.75 TDP1 (0.45) GPR35TDP1KMT2AMEN1HSD17B10
SCHEMBL8374 0.75 TDP1 (0.54) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL9336847 0.75 GPR35 (0.54) GPR35TDP1KMT2AMEN1MAPK1
SCHEMBL2193448 0.75 TDP1 (0.45) GPR35TDP1KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2079757-B1 PROCESS FOR SELECTIVELY LOCALIZING ACTIVE INGREDIENTS ON AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE INGREDIENTS UGICHEM GES FÜR ORGANISCHE CHEMIE MBH (AT) 2014-12-17 EP claimed
US-20130101517-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-04-25 US claimed
EP-2550338-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING National University of Singapore (SG) 2013-01-30 EP claimed
WO-2011119114-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING NATIONAL UNIVERSITY OF SINGAPORE (SG) 2011-09-29 WO claimed
US-20100261765-A1 MINERALOCORTICOID RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2010-10-14 US claimed
EP-2229167-A1 MINERALOCORTICOID RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2010-09-22 EP claimed
WO-2009078934-A1 MINERALOCORTICOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2009-06-25 WO claimed
EP-0886640-B1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GLYCOMIMETICS INC (US) 2007-03-21 EP claimed
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 US claimed
US-20040102650-A1 Solid phase synthesis of arylretinamides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-05-27 US claimed
US-20030105164-A1 Solid phase synthesis of arylretinamides NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-05 US claimed
WO-2003003987-A2 SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2003-01-16 WO claimed
US-6169077-B1 A SIALYLATED AND FUCOSYLATED CARBOHYDRATE; USE AS ANTIADHESION THERAPEUTICS TREATING INFLAMMATIONS, THEY CAN PREVENT THE SELECTIN RECEPTORS FROM BINDING TO ACTIVATED ENDOTHELIAL CELLS ON THE SURFACE OF LEUCOCYTES GLYCOTECH CORP. 2001-01-02 US claimed
EP-0886640-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GlycoTech Corp. (US) 1998-12-30 EP claimed
WO-1997028173-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES NOVARTIS AG (CH) 1997-08-07 WO claimed
EP-0370492-B1 INDOLE-ALDEHYDE HAIR DYES Bristol-Myers Squibb Company (US) 1993-01-27 EP claimed
US-5108502-A Azo dyes; water solubility; utility in inks for ink-jet printing HEWLETT-PACKARD COMPANY (US) 1992-04-28 US claimed
US-4932977-A Indole-aldehyde hair dyes CLAIROL INCORPORATED (US) 1990-06-12 US claimed
EP-0370492-A1 Indole-aldehyde hair dyes Bristol-Myers Squibb Company (US) 1990-05-30 EP claimed
WO-2024108068-A2 METHODS OF EVALUATING VIRUS-PRODUCING CELLS BRUKER CELLULAR ANALYSIS, INC. (US) 2024-05-23 WO disclosed
WO-2024077101-A2 COMPOSITIONS FOR MICROFLUDIC WORKFLOWS AND METHODS OF USE THEREOF BRUKER CELLULAR ANALYSIS, INC. (US) 2024-04-11 WO disclosed
WO-2024076923-A1 MICRO-OBJECT DISPLACEMENT WITHIN A MICROFLUIDIC ENVIRONMENT BRUKER CELLULAR ANALYSIS, INC. (US) 2024-04-11 WO disclosed
US-20230375447-A1 METHOD FOR ASSAYING A MICRO-OBJECT WITHIN A MICROFLUIDIC DEVICE BRUKER SPATIAL BIOLOGY, INC. 2023-11-23 US disclosed
WO-2023147334-A9 METHODS OF ASSAYING MICRO-OBJECTS IN A MICROFLUIDIC DEVICE Berkeley Lights, Inc. (US) 2023-08-31 WO disclosed
WO-2023164623-A2 APPARATUSES, METHODS, AND KITS FOR MICROFLUIDIC ASSAYS Berkeley Lights, Inc. (US) 2023-08-31 WO disclosed
WO-2023147334-A1 METHODS OF ASSAYING MICRO-OBJECTS IN A MICROFLUIDIC DEVICE Berkeley Lights, Inc. (US) 2023-08-03 WO disclosed
US-20230182136-A1 IN SITU-GENERATED MICROFLUIDIC ISOLATION STRUCTURES, KITS AND METHODS OF USE THEREOF Berkeley Lights, Inc. (US) 2023-06-15 US disclosed
US-11666913-B2 In situ-generated microfluidic isolation structures, kits and methods of use thereof BERKELEY LIGHTS, INC (US) 2023-06-06 US disclosed
CN-111225900-A 3, 4-disubstituted 3-cyclobutene-1, 2-diones and their use 阿勒根公司 2020-06-02 CN disclosed
EP-3380238-A1 IN SITU-GENERATED MICROFLUIDIC ISOLATION STRUCTURES, KITS AND METHODS OF USE THEREOF Berkeley Lights, Inc. (US) 2018-10-03 EP disclosed
US-20170165667-A1 IN SITU-GENERATED MICROFLUIDIC ISOLATION STRUCTURES, KITS AND METHODS OF USE THEREOF BRUKER CELLULAR ANALYSIS, INC. 2017-06-15 US disclosed
US-20170079954-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2017-03-23 US disclosed
US-9540351-B2 Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2017-01-10 US disclosed
EP-3046918-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS Axikin Pharmaceuticals, Inc. (US) 2016-07-27 EP disclosed
US-9382237-B2 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9365556-B2 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2016-06-14 US disclosed
US-9346792-B2 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2016-05-24 US disclosed
CN-105198872-A Chromenone analogs as sirtuin modulators SIRTRIS PHARMACEUTICALS INC 2015-12-30 CN disclosed
US-9201014-B2 Development of photostable near-IR cyanine dyes for in vivo imaging NATIONAL UNIVERSITY OF SINGAPORE (SG) 2015-12-01 US disclosed
CN-102227417-B Chromenone analogs as sirtuin modulators SIRTRIS PHARMACEUTICALS, INC. (US) 2015-09-16 CN disclosed
US-20150105389-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2015-04-16 US disclosed
EP-2852586-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS Axikin Pharmaceuticals, Inc. (US) 2015-04-01 EP disclosed
WO-2015042111-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. (US) 2015-03-26 WO disclosed
US-20150080398-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2015-03-19 US disclosed
US-20150080397-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2015-03-19 US disclosed
EP-2834232-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS Axikin Pharmaceuticals, Inc. (US) 2015-02-11 EP disclosed
CN-104334545-A 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS INC 2015-02-04 CN disclosed
CN-104302640-A 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS INC 2015-01-21 CN disclosed
US-8916555-B2 3,5-diaminopyrazole kinase inhibitors AXIKIN PHARMACEUTICALS, INC. (US) 2014-12-23 US disclosed
US-20130303492-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. 2013-11-14 US disclosed
US-20130274227-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. (US) 2013-10-17 US disclosed
WO-2013138617-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. (US) 2013-09-19 WO disclosed
WO-2013138613-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS AXIKIN PHARMACEUTICALS, INC. (US) 2013-09-19 WO disclosed
EP-2638047-A1 SUBSTITUTED 4-BETA-ACRYLAMIDOPODOPHYLLOTOXIN CONGENERS AS ANTITUMOUR ANTIBIOTICS AND THE PROCESS FOR PREPARATION THEREOF Council of Scientific and Industrial Research (IN) 2013-09-18 EP disclosed
US-20130189727-A1 Methods And Compositions For Cellular Imaging And Cancer Cell Detection Using Light Harvesting Conjugated Polymer-Biomolecular Conjugates NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-07-25 US disclosed
US-20130109029-A1 Methods And Compositions For Cellular Imaging And Cancer Cell Detection Using Light Harvesting Conjugated Polymer-Biomolecular Conjugates NATIONAL UNIVERSITY OF SINGAPORE (SG) 2013-05-02 US disclosed
US-20130101517-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2013-04-25 US disclosed
EP-2550338-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING National University of Singapore (SG) 2013-01-30 EP disclosed
WO-2012063250-A1 SUBSTITUTED 4-BETA-ACRYLAMIDOPODOPHYLLOTOXIN CONGENERS AS ANTITUMOUR ANTIBIOTICS AND THE PROCESS FOR PREPARATION THEREOF COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2012-05-18 WO disclosed
WO-2012002911-A1 METHODS AND COMPOSITIONS FOR CELLULAR IMAGING AND CANCER CELL DETECTION USING LIGHT HARVESTING CONJUGATED POLYMER- BIOMOLECULAR CONJUGATES NATIONAL UNIVERSITY OF SINGAPORE (SG) 2012-01-05 WO disclosed
WO-2011119114-A1 DEVELOPMENT OF PHOTOSTABLE NEAR-IR CYANINE DYES FOR IN VIVO IMAGING NATIONAL UNIVERSITY OF SINGAPORE (SG) 2011-09-29 WO disclosed
WO-2010146351-A1 INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2010-12-23 WO disclosed
US-20100261765-A1 MINERALOCORTICOID RECEPTOR MODULATORS MERCK SHARP & DOHME CORP. 2010-10-14 US disclosed
EP-2229167-A1 MINERALOCORTICOID RECEPTOR MODULATORS Merck Sharp & Dohme Corp. (US) 2010-09-22 EP disclosed
CN-101547934-A Process for selectively localizing active ingredients on and in mitochondria and corresponding active ingredients UGICHEM GES FUER ORGANISCHE CH (AT) 2009-09-30 CN disclosed
EP-2079757-A2 PROCESS FOR SELECTIVELY LOCALIZING ACTIVE INGREDIENTS ON AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE INGREDIENTS Ugichem Gesellschaft Für Organische Chemie MbH (AT) 2009-07-22 EP disclosed
WO-2009078934-A1 MINERALOCORTICOID RECEPTOR MODULATORS MERCK & CO., INC. (US) 2009-06-25 WO disclosed
US-7550510-B2 Solid phase synthesis of arylretinamides WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-06-23 US disclosed
CN-101454287-A Substituted cyanopyridines as protein kinase inhibitors WYETH CORP (US) 2009-06-10 CN disclosed
WO-2008049583-A3 PROCESS FOR SELECTIVELY LOCALIZING ACTIVE INGREDIENTS ON AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE INGREDIENTS UGICHEM GES FUER ORGANISCHE CH (AT) 2009-04-16 WO disclosed
WO-2008049583-A2 PROCESS FOR SELECTIVELY LOCALIZING ACTIVE INGREDIENTS ON AND IN MITOCHONDRIA AND CORRESPONDING ACTIVE INGREDIENTS Ugichem Gesellschaft für Organische Chemie mbH (AT) 2008-05-02 WO disclosed
US-7335411-B2 Method of producing a tire composition having improved silica reinforcement BRIDGESTONE CORPORATION (JP) 2008-02-26 US disclosed
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INC. 2007-11-01 US disclosed
EP-0886640-B1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GLYCOMIMETICS INC (US) 2007-03-21 EP disclosed
US-20060089446-A1 Method of producing a tire composition having improved silica reinforcement BRIDGESTONE CORPORATION 2006-04-27 US disclosed
US-20060084176-A1 Detection of uronium salts YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-04-20 US disclosed
US-20040102650-A1 Solid phase synthesis of arylretinamides NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-05-27 US disclosed
CN-1146541-C Beta-alanine derivatives Ĭ��ר���ɷ����޹�˾ 2004-04-21 CN disclosed
US-6696606-B2 REACTING HEXACHLOROACETONE WITH TRIPHENYLPHOSPHINE; CHLORINATION OF RETINOIC ACID; THEN AROMATIC AMINE; ANTICANCER AGENTS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION 2004-02-24 US disclosed
US-6576637-B1 Such as 3-(4-methyl-3-nitrophenyl)-3-(2-(4-(pyridin-2-yl-amino)butyryl amino)acetylamino)propionic acid; thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, inflammations, MERCK PATENT GMBH (DE) 2003-06-10 US disclosed
US-20030105164-A1 Solid phase synthesis of arylretinamides NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2003-06-05 US disclosed
WO-2003003987-A2 SOLID PHASE SYNTHESIS OF ARYLRETINAMIDES THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2003-01-16 WO disclosed
CN-1340046-A Beta-alanine derivatives MERCK PATENT GMBH (DE) 2002-03-13 CN disclosed
EP-1153014-A2 BETA-ALANINE DERIVATIVES MERCK PATENT GmbH (DE) 2001-11-14 EP disclosed
US-6169077-B1 A SIALYLATED AND FUCOSYLATED CARBOHYDRATE; USE AS ANTIADHESION THERAPEUTICS TREATING INFLAMMATIONS, THEY CAN PREVENT THE SELECTIN RECEPTORS FROM BINDING TO ACTIVATED ENDOTHELIAL CELLS ON THE SURFACE OF LEUCOCYTES GLYCOTECH CORP. 2001-01-02 US disclosed
WO-2000048996-A2 β-ALANINE DERIVATIVES MERCK PATENT GMBH (DE) 2000-08-24 WO disclosed
EP-0886640-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES GlycoTech Corp. (US) 1998-12-30 EP disclosed
WO-1997028173-A1 SIALYL-LEWISa AND SIALYL-LEWISx EPITOPE ANALOGUES NOVARTIS AG (CH) 1997-08-07 WO disclosed
US-5399589-A Oxalyl hydrazide-hydroxamic acid derivatives, their preparation and their use as fungicides BASF AKTIENGESELLSCHAFT (DE) 1995-03-21 US disclosed
EP-0602561-A1 Oxalylhydrazide-hydroxamic acid derivatives, process for their preparation and their use as fungicides BASF Aktiengesellschaft (DE) 1994-06-22 EP disclosed
US-5283325-A Anionic dyes for polyamides, oxide layers on aluminum and its alloys SANDOZ LTD. (CH) 1994-02-01 US disclosed
US-5191073-A Indicators for colorimetric analysis of enzymes MILES INC. (US) 1993-03-02 US disclosed
EP-0370492-B1 INDOLE-ALDEHYDE HAIR DYES Bristol-Myers Squibb Company (US) 1993-01-27 EP disclosed
US-5122602-A Optical indicators; medical diagnosis; quantitative analysis; immunoassay MILES INC. (US) 1992-06-16 US disclosed
US-5108502-A Azo dyes; water solubility; utility in inks for ink-jet printing HEWLETT-PACKARD COMPANY (US) 1992-04-28 US disclosed
EP-0368225-B1 HYDROXYL AMINE DERIVATIVES BASF Aktiengesellschaft (DE) 1992-04-15 EP disclosed
US-5081301-A HYDROXYLAMINE DERIVATIVES WHICH ARE INTERMEDIATES FOR MAKING HERBICIDAL COMPOUNDS BASF AKTIENGESELLSCHAFT (DE) 1992-01-14 US disclosed
EP-0383092-A2 Chromogenic merocyanine enzyme substrates Bayer Corporation (US) 1990-08-22 EP disclosed
US-4932977-A Indole-aldehyde hair dyes CLAIROL INCORPORATED (US) 1990-06-12 US disclosed
EP-0370492-A1 Indole-aldehyde hair dyes Bristol-Myers Squibb Company (US) 1990-05-30 EP disclosed
EP-0368225-A1 Hydroxyl amine derivatives BASF Aktiengesellschaft (DE) 1990-05-16 EP disclosed
US-4048333-A Method for treating a picorna virus infection MEDIZINSKA AKADEMIA (BG) 1977-09-13 US disclosed
US-4048333-A Method for treating a picorna virus infection MEDIZINSKA AKADEMIA (BG) 1977-09-13 US disclosed
US-4048333-A Method for treating a picorna virus infection MEDIZINSKA AKADEMIA (BG) 1977-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130274227-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, MAP3K1 GPR35 2069/4885TDP1 928/4885KMT2A 2811/4885
US-20170079954-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS GRK3, DMPK, PRKAG3 GPR35 910/4885TDP1 1234/4885KMT2A 3524/4885
US-20070254917-A1 INTRACELLULAR RECEPTOR MODULATOR COMPOUNDS AND METHODS CASR, GRK2, RYR2 GPR35 203/4885TDP1 4046/4885KMT2A 4345/4885
US-20150080398-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, MAP3K1 GPR35 2069/4885TDP1 928/4885KMT2A 2811/4885
US-20100261765-A1 MINERALOCORTICOID RECEPTOR MODULATORS NR3C2, MC2R, NR3C1 GPR35 84/4885TDP1 4480/4885KMT2A 3249/4885
US-20150105389-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, MAP3K1 GPR35 2069/4885TDP1 928/4885KMT2A 2811/4885
US-20150080397-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS GRK3, DMPK, PRKAG3 GPR35 910/4885TDP1 1234/4885KMT2A 3524/4885
US-20130303492-A1 3,5-DIAMINOPYRAZOLE KINASE INHIBITORS MAP3K13, MAP3K3, MAP3K1 GPR35 2069/4885TDP1 928/4885KMT2A 2811/4885
US-20040102650-A1 Solid phase synthesis of arylretinamides RARA, LRAT, NR2E3 GPR35 149/4885TDP1 3490/4885KMT2A 527/4885
US-20030105164-A1 Solid phase synthesis of arylretinamides RARA, LRAT, NR2E3 GPR35 149/4885TDP1 3490/4885KMT2A 527/4885
US-20130109029-A1 Methods And Compositions For Cellular Imaging And Cancer Cell Detection Using Light Harvesting Conjugated Polymer-Biomolecular Conjugates CA14, EPCAM, CA12 GPR35 3057/4885TDP1 2910/4885KMT2A 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.